Cancer Immunology – News and Features

Ablynx has announced it has expanded its nearly year-and-a-half-old immuno-oncology collaboration with Merck & Co. to address additional checkpoint modulator targets.

Xoma have announced that their monoclonal antibody gevokizumab it is co-developing with Servier has failed the Phase III EYEGUARD-B trial in patients with Behçet's disease uveitis.

A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.

Study has been published in Nature Medicine.

The company has announced that positive data from its Phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published.

The company have announced the success of atezolizumab in shrinking tumors people with locally advanced or metastatic urothelial bladder cancer.

PharmAthene has agreed to develop and commercialize a recombinant Protective Antigen (rPA)anthrax vaccine candidate using Immunovaccine's DepoVax™ vaccine platform.

Combination aims to achieve high levels of activation of CART cells in tumors with reduced toxicity in normal tissues.

Company has signed an exclusive licensing agreement with Excelimmune to access ACT platform.

The expanded collaboration will focus on developing immuno-oncology mouse models and other disease-specific experimental models supporting translational medical research.